🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Click Therapeutics is attending the American Headache Society 66th Annual Scientific Meeting on June 13! Stop by our booth to learn more on the future of migraine treatment with our digital therapeutic, CT-132, that is wrapping up Phase 3 trials. Learn more: americanheadachesociety.org/events/66th-an…

From NYSE: The founder of Click Therapeutics™ on the digital therapeutics space and the regulatory opportunity for combining medicines with apps. Full video: biotechtv.com/post/click-the…

Along with Otsuka Precision Health, we are proud to announce the launch of Rejoyn™, the first and only FDA-authorized prescription digital therapeutic for the adjunctive treatment of MDD symptoms for adults 22+ on an antidepressant. To learn more, visit rejoyn.com.

Attending the 7th Neuropsychiatric Drug Development Summit today? Join us as Click’s CMO, Shaheen Lakhan takes the stage in “How Patient-Centric Prescription Digital Therapeutics Can Improve Clinical Outcomes” at 4:30 PM ET. See the full agenda here: neuropsychiatric-drug-development.com/whats-on/agend…

Click Therapeutics has been nominated for the 2024 Prix Galien USA Award in the "Best Startup" category. We're honored to be among the top innovators and look forward to the Awards Ceremony in November!

Click is honored to share that our CEO David Benshoof Klein has been named to the 2024 PharmaVoice 100 list, recognizing him as a top leader in the life-sciences industry within Tech and AI. Check out the full list of inspiring leaders: pharmavoice.com/news/pv100-pha… #PharmaVoice100

Click is headed to Berlin for the Frontiers Health Congress taking place October 17-18. Our CEO & Founder, David Benshoof Klein, will take the stage to share his insights on the future of medicine in a keynote and fireside chat. Learn more: frontiers.health/2024-agenda

In his latest article for MedCity News , our CMO Shaheen Lakhan explores how smartphones and social media contribute to a growing mental health crisis - and how the same technology that poses risks can also offer transformative health benefits. Learn more: medcitynews.com/2024/12/the-sa…

Click Therapeutics Founder and Chief Executive Officer David Benshoof Klein shared his predictions for the pharma industry in 2025 in Healthcare IT Today. To learn more on David's insights for the new year, read the full article at: healthcareittoday.com/2025/01/03/pha…

BREAKING NEWS: Dassault Systèmes and Medidata have made a strategic investment in Click Therapeutics™. 25 years ago we revolutionized clinical trials. Today, we’re expanding the boundaries of healthcare by combining cutting-edge science with the power of software to develop new, cutting-edge

Today, Dassault Systèmes Medidata announced a strategic investment in Click, having provided the entire Series C funding round. The collaboration will provide a clear path to best-in-class PDTs and Software-Enhanced Drugs™ product approvals. Learn more: medidata.com/en/about-us/ne…

Click Therapeutics Founder & CEO, David Benshoof Klein, delivered a keynote address at Medidata NEXT in London last week, where Click announced closing its Series C investment round, provided entirely by Dassault Systèmes . Read more here: clicktherapeutics.com/news/click-the…

Click was honored to present a poster at the AAN annual meeting on the effectiveness and safety of our first-in-class investigational PDT for the preventive treatment of episodic migraine. Read more at: medscape.com/viewarticle/fi… #AANAM #AAN2025

CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in patients 18 years of age and older, has received FDA marketing authorization. Learn more: clicktherapeutics.com/news/click-the…

Click will present Phase 3 data from the ReMMiD-C bridging study of CT-132 at the American Headache Society 2025 Annual Scientific Meeting on Saturday, June 21 at 9:10 AM CST. Cassandra Snipes, PhD, will present abstract IOR-05. Learn more: ahsam25.eventscribe.net/fsPopup.asp?Pr… #AHSAM

We’re proud to share that our Founder and CEO, David Klein, is a finalist for EY US Entrepreneur Of The Year New York! This honor recognizes David’s commitment to innovation and his impact on the future of patient care. Congrats to all the finalists! ey.com/en_us/entrepre…

Is tech friend or foe to our brains? It depends how we use it. In Medscape, our CMO Shaheen Lakhan shares insights on how digital tools can erode or nourish cognitive health. At Click, we build treatments that turn tech into a tool for good. Read more: medscape.com/viewarticle/di…

CT-132, Click’s prescription digital therapeutic for migraine prevention, was featured in NeurologyLive® with insights from Eric Baron, DO of Cleveland Clinic. He shares how this FDA-authorized, app-based treatment can complement existing therapies: neurologylive.com/view/eric-baro…

Click will be at #ASCO25, where our CMO Shaheen Lakhan, MD, PhD, FAAN will present our innovative oncology research. Visit us at Booth #13093, and reach out to [email protected] to request a meeting. Learn more: meetings.asco.org/meetings/2025-… ASCO

We’re heading to #BIO2025! Join Click at Booth 3678 where our team will be on-site and available for meetings to explore strategic partnerships across PDTs and Software-Enhanced Drug™ therapies. Looking to connect? Contact [email protected]